IRIS
Cao, Davide
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.887
AS - Asia 2.164
EU - Europa 748
SA - Sud America 355
Continente sconosciuto - Info sul continente non disponibili 104
AF - Africa 50
OC - Oceania 5
Totale 6.313
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.809
SG - Singapore 1.224
CN - Cina 503
BR - Brasile 300
VN - Vietnam 196
DE - Germania 192
FI - Finlandia 149
IT - Italia 117
IE - Irlanda 80
IN - India 50
FR - Francia 48
GB - Regno Unito 44
HK - Hong Kong 44
SE - Svezia 41
CA - Canada 35
MX - Messico 24
IQ - Iraq 23
AR - Argentina 22
BD - Bangladesh 22
PL - Polonia 14
ES - Italia 13
RU - Federazione Russa 13
JP - Giappone 12
ZA - Sudafrica 12
TR - Turchia 11
EG - Egitto 10
ID - Indonesia 10
NG - Nigeria 10
PK - Pakistan 10
NL - Olanda 9
MA - Marocco 7
MY - Malesia 7
PY - Paraguay 7
CO - Colombia 6
UA - Ucraina 6
VE - Venezuela 6
EC - Ecuador 5
JM - Giamaica 5
NP - Nepal 5
SA - Arabia Saudita 5
TH - Thailandia 5
AU - Australia 4
AZ - Azerbaigian 4
BE - Belgio 4
JO - Giordania 4
KZ - Kazakistan 4
UZ - Uzbekistan 4
AL - Albania 3
BB - Barbados 3
CL - Cile 3
CU - Cuba 3
KE - Kenya 3
PE - Perù 3
PH - Filippine 3
PT - Portogallo 3
AE - Emirati Arabi Uniti 2
AF - Afghanistan, Repubblica islamica di 2
BO - Bolivia 2
CR - Costa Rica 2
DZ - Algeria 2
EE - Estonia 2
IL - Israele 2
LB - Libano 2
LT - Lituania 2
SY - Repubblica araba siriana 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
AT - Austria 1
BH - Bahrain 1
CH - Svizzera 1
CI - Costa d'Avorio 1
CY - Cipro 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
GD - Grenada 1
GR - Grecia 1
IM - Isola di Man 1
IR - Iran 1
KR - Corea 1
KW - Kuwait 1
LU - Lussemburgo 1
MN - Mongolia 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
OM - Oman 1
PA - Panama 1
RO - Romania 1
RS - Serbia 1
SN - Senegal 1
TG - Togo 1
TW - Taiwan 1
UG - Uganda 1
UY - Uruguay 1
Totale 6.209
Salva come PNG Salva come JPEG
Città #
Dallas 577
Singapore 524
San Jose 334
Ashburn 330
The Dalles 209
Shanghai 180
Beijing 151
Helsinki 148
Falkenstein 128
Council Bluffs 120
Boardman 104
New York 99
Chandler 90
Dublin 79
Ho Chi Minh City 68
Los Angeles 59
Milan 48
Wilmington 48
Hanoi 45
Santa Clara 45
Hong Kong 42
São Paulo 27
San Mateo 24
Pune 19
Ann Arbor 17
Buffalo 17
Seattle 15
Brooklyn 13
Rome 13
Assago 12
Chicago 12
Phoenix 12
Stockholm 12
Warsaw 11
Benin City 10
Lawrence 10
Mexico City 10
Montreal 10
Munich 10
Princeton 10
Leawood 9
Paris 9
Rio de Janeiro 9
Curitiba 8
Da Nang 8
Lauterbourg 8
London 8
Philadelphia 8
Porto Alegre 8
Baghdad 7
Naples 7
Orem 7
San Francisco 7
Tokyo 7
Amsterdam 6
Denver 6
Fairfield 6
Haiphong 6
Houston 6
Toronto 6
Abbiategrasso 5
Asunción 5
Belo Horizonte 5
Biên Hòa 5
Columbus 5
Dhaka 5
Düsseldorf 5
Frankfurt am Main 5
Johannesburg 5
New Delhi 5
Reston 5
Santo André 5
Woodbridge 5
Boston 4
Brasília 4
Brussels 4
Campinas 4
Changsha 4
Charlotte 4
Kingston 4
Manchester 4
Mumbai 4
Shijiazhuang 4
Tashkent 4
Thái Bình 4
Al Fayyum 3
Amman 3
Ankara 3
Atlanta 3
Betim 3
Bridgetown 3
Bắc Giang 3
Caxias do Sul 3
Chennai 3
Erbil 3
Goiânia 3
Greenville 3
Havana 3
Irvine 3
Istanbul 3
Totale 3.996
Salva come PNG Salva come JPEG
Nome #
1- Versus 3-Month DAPT in Older Patients at a High Bleeding Risk Undergoing PCI: Insights from the XIENCE Short DAPT Global Program 651
Direct oral anticoagulants in addition to antiplatelet therapy for secondary prevention after acute coronary syndromes: an updated systematic review and meta-analysis 148
Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis. 140
On the Modeling of Patient-Specific Transcatheter Aortic Valve Replacement: A Fluid–Structure Interaction Approach 98
The synergy stent in high-bleeding risk patients: why design matters 86
Clinical Outcomes and Revascularization Strategies in Patients With Low-Flow, Low-Gradient Severe Aortic Valve Stenosis According to the Assigned Treatment Modality 86
Coronary Artery Disease Severity and Aortic Stenosis: Clinical Outcomes According to SYNTAX-Score in Patients Undergoing Transcatheter Aortic Valve Implantation 85
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent 79
Impact of High-Density Lipoprotein Levels on Cardiovascular Outcomes of Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents 76
A contemporary simple risk score for prediction of contrast-associated acute kidney injury after percutaneous coronary intervention: derivation and validation from an observational registry 72
Device profile of the Resolute Onyx Zotarolimus eluting coronary stent system for the treatment of coronary artery disease: overview of its safety and efficacy 71
Coronary Revascularisation in Transcatheter Aortic Valve Implantation Candidates: Why, Who, When? 71
Short Versus Long Duration of DAPT After DES Implantation: A Meta-Analysis. 71
Aspirin-free strategies: a framework to reassess the role of dual antiplatelet therapy after percutaneous coronary intervention 68
Contrast-induced acute kidney injury 67
Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR 66
Comparative influence of bleeding and ischemic risk factors on diabetic patients undergoing percutaneous coronary intervention with everolimus-eluting stents 66
Impact of anemia on short-term outcomes after TAVR: A subgroup analysis from the BRAVO-3 randomized trial 66
Radial versus femoral access for coronary interventions: An updated systematic review and meta-analysis of randomized trials 65
Depression and ischemic heart disease 65
Impact of Race/Ethnicity on Long Term Outcomes After Percutaneous Coronary Intervention with Drug-Eluting Stents 64
Revascularization in patients with valvular heart disease 64
Non-cardiac surgery in patients with coronary artery disease: risk evaluation and periprocedural management 63
Prognostic Impact of High-Sensitivity C-Reactive Protein in Patients Undergoing Percutaneous Coronary Intervention According to BMI 62
Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI 61
Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey 61
Impact of renal function in high bleeding risk patients undergoing percutaneous coronary intervention: a patient-level stratified analysis from four post-approval studies 60
Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with acute coronary syndrome: a meta-analysis 60
3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation 60
Platelets and the Atherosclerotic Process: An Overview of New Markers of Platelet Activation and Reactivity, and Their Implications in Primary and Secondary Prevention 60
Sex-Related Differences in Patients at High Bleeding Risk Undergoing Percutaneous Coronary Intervention: A Patient-Level Pooled Analysis From 4 Postapproval Studies 59
Prognostic Value of Baseline Inflammation in Diabetic and Nondiabetic Patients Undergoing Percutaneous Coronary Intervention 58
Impact of Small Valve Size on 1-Year Outcomes After Transcatheter Aortic Valve Implantation in Women (from the WIN-TAVI Registry) 58
Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis 58
Evolution of drug-eluting coronary stents: a back-and-forth journey from the bench-to-bedside 58
Assessing the risk of acute kidney injury after primary PCI: The simpler the sooner the better 58
A sex paradox in clinical outcomes following complex percutaneous coronary intervention 58
Residual SYNTAX Score and One-Year Outcome in Elderly Patients With Acute Coronary Syndrome 57
Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index 57
PROGNOSTIC VALUE OF HIGH-SENSITIVITY C-REATIVE PROTEIN AMONG CHRONIC KIDNEY DISEASE PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION 56
Edge-to-edge percutaneous mitral repair for functional ischaemic and non-ischaemic mitral regurgitation: a systematic review and meta-analysis 55
Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials 54
Effect of Elevated C-Reactive Protein on Outcomes After Complex Percutaneous Coronary Intervention for Angina Pectoris 54
Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD 54
Impact of target vessel choice on outcomes following percutaneous coronary intervention in patients with a prior coronary artery bypass graft 53
Validation of the Academic Research Consortium High Bleeding Risk Definition in Contemporary PCI Patients 53
Incidence, predictors and impact of stroke on mortality among patients with acute coronary syndromes following percutaneous coronary intervention-Results from the PROMETHEUS registry 52
Prevalence and Impact of High Bleeding Risk in Patients Undergoing Left Main Artery Disease PCI 52
Clinical outcomes after TAVR with heparin or bivalirudin as periprocedural anticoagulation in patients with and without peripheral arterial disease: Results from the BRAVO-3 randomized trial 52
Incidence, predictors and clinical impact of permanent pacemaker insertion in women following transcatheter aortic valve implantation: Insights from a prospective multinational registry 51
Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review 51
Clopidogrel Monotherapy After 1-Month DAPT in Diabetic Patients Undergoing PCI: Is Less Always More? 51
Perioperative risk and antiplatelet management in patients undergoing non-cardiac surgery within 1 year of PCI 51
Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD 51
ARC-HBR criteria and TAVR: not all high bleeding risk patients look alike 50
Efficacy and Safety of P2Y12 Inhibitor Monotherapy After Complex PCI: A Collaborative Systematic Review and Meta-Analysis 50
Recent Advances in Antiplatelet Therapy in Complex Percutaneous Coronary Intervention 50
Types of myocardial injury and mid-term outcomes in patients with COVID-19 49
Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI: A Prespecified TWILIGHT Substudy 49
Reversal and removal of oral antithrombotic drugs in patients with active or perceived imminent bleeding 49
The mega COMBO collaboration: An individual patient data pooled analysis of patients undergoing PCI with COMBO stent 48
Sex-Related Outcomes of Medical, Percutaneous, and Surgical Interventions for Coronary Artery Disease: JACC Focus Seminar 3/7 48
Pericardial Effusion Provoking Atrial Fibrillation After Cardiac Surgery: JACC Review Topic of the Week 48
New Criteria to Identify Patients at Higher Risk for Cardiovascular Complications After Percutaneous Coronary Intervention 47
Impact of diabetes mellitus on short term vascular complications after TAVR: Results from the BRAVO-3 randomized trial 47
Preprocedural anemia in females undergoing transcatheter aortic valve implantation: Insights from the WIN-TAVI registry 47
Treating Inflammation Prior to Percutaneous Coronary Intervention: Does the Heart Care? 47
Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study 47
One-Month Versus Three-Month Dual-Antiplatelet Therapy in High Bleeding Risk Patients With Chronic Kidney Disease 46
Predictors of antiplatelet cessation in a real-world patient population undergoing non-cardiac surgery after PCI 46
Prevalence and prognostic impact of hsCRP elevation are age-dependent in women but not in men undergoing percutaneous coronary intervention 45
The impact of chronic kidney disease in women undergoing transcatheter aortic valve replacement: Analysis from the Women's INternational Transcatheter Aortic Valve Implantation (WIN-TAVI) registry 45
Management of Adults With Anomalous Aortic Origin of the Coronary Arteries: State-of-the-Art Review 44
Clinical and procedural outcomes of percutaneous coronary intervention for de novo lesions involving the ostial left circumflex coronary artery 44
P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events 44
Impact of diabetes mellitus on female subjects undergoing transcatheter aortic valve implantation: Insights from the WIN-TAVI international registry 44
Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI 43
From surgical clamping to endovascular flow arrest/reversal: the concept behind the system 42
Ticagrelor Monotherapy After Coronary Stenting: Is the GLASS Half Full or Half Empty? 42
Minding the Microcirculation: Is it Worth the Effort? 41
Ticagrelor With or Without Aspirin in High-Risk Patients With Anemia Undergoing Percutaneous Coronary Intervention: a subgroup analysis of the TWILIGHT trial 41
Vitamin D and Cardiovascular Diseases: From Physiology to Pathophysiology and Outcomes 41
Impact of sex on long-term cardiovascular outcomes of patients undergoing percutaneous coronary intervention for acute coronary syndromes 40
Perioperative Management of P2Y12 Inhibitors in Patients Undergoing Cardiac Surgery within 1 Year of PCI 40
Sex-Related Differences in the Prevalence and Prognostic Value of the Academic Research Consortium for High Bleeding Risk Criteria 40
Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention 40
Rethinking the Role of Impaired Renal Function in Multivessel PCI or CABG 40
Ticagrelor in Patients With Cancer: 2 Birds With 1 Stone 39
Uninterrupted direct-acting oral anticoagulation in patients undergoing transradial percutaneous coronary procedures: The DOAC-NOSTOP study rationale and design 39
Left Atrial Appendage Closure Compared With Oral Anticoagulants for Patients With Atrial Fibrillation: A Systematic Review and Network Meta-Analysis 38
Stick to the guidelines or clinical judgment: A toss up? 38
Periprocedural anticoagulation in non-ST-segment elevation acute coronary syndrome: time to reassess? 38
Sodium Bicarbonate, Contrast-Associated Acute Kidney Injury, and Long-Term Outcomes: The End of an Era? 37
SGLT-2 inhibitors and cardiovascular outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis 37
Predictive value of the thrombotic risk criteria proposed in the 2023 ESC guidelines for the management of ACS: insights from a large PCI registry 36
Subjective angina or myocardial ischaemia to justify PCI? Never mistake the finger for the moon 36
Performance of the academic research consortium high-bleeding risk criteria in patients undergoing PCI for acute myocardial infarction 35
First and recurrent events in the ISCHEMIA trial: two sides of the same coin 34
Thrombotic risk in patients with acute coronary syndromes discharged on prasugrel or clopidogrel: results from the PROMETHEUS study 33
Impact of complex percutaneous coronary intervention features on clinical outcomes in patients with or without chronic kidney disease 33
Totale 6.080
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.852
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.852
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202254 0 2 0 13 2 1 0 6 5 2 15 8
2022/2023487 21 5 13 43 33 30 77 27 92 99 38 9
2023/2024686 69 51 152 37 12 84 51 14 23 37 81 75
2024/20251.095 22 3 17 11 19 139 70 83 198 282 137 114
2025/20263.564 407 294 539 241 127 150 886 219 164 215 112 210
2026/2027323 105 218 0 0 0 0 0 0 0 0 0 0
Totale 6.313